Article

29 views

Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen.
It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.

Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen.
It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in New Drug Approvals


New Drug Approvals

FDA Approves Best-Selling Drugs Combo, ‘Venclexta plus Rituxan’ to Treat Two Common Blood Cancers

Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen. It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply